UBS Reiterates Neutral Rating on Praxis Precision Medicines Inc. (PRAX)

October 14, 2026 4:45 PM

UBS reiterated a Neutral rating and $706.00 price target on Praxis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found